Prevention of Diabetes With Pioglitazone in ACT NOW: Physiologic Correlates

We examined the metabolic characteristics that attend the development of type 2 diabetes (T2DM) in 441 impaired glucose tolerance (IGT) subjects who participated in the ACT NOW Study and had complete end-of-study metabolic measurements. Subjects were randomized to receive pioglitazone (PGZ; 45 mg/da...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: DeFronzo, Ralph A., Tripathy, Devjit, Schwenke, Dawn C., Banerji, MaryAnn, Bray, George A., Buchanan, Thomas A., Clement, Stephen C., Gastaldelli, Amalia, Henry, Robert R., Kitabchi, Abbas E., Mudaliar, Sunder, Ratner, Robert E., Stentz, Frankie B., Musi, Nicolas, Reaven, Peter D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Diabetes Association 2013
Aiheet:
Original Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3806596/
https://ncbi.nlm.nih.gov/pubmed/23863810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db13-0265
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia